Non-cancerous stromal cells represent a highly diverse compartment of the tumour, yet their role across tumour evolution remains unclear. We employed single-cell RNA sequencing to determine stromal adaptations in murine melanoma at different points of tumour development. Naive lymphocytes recruited from lymph nodes underwent activation and clonal expansion within the tumour, prior to PD1 and Lag3 expression, while tumourassociated myeloid cells promoted the formation of a suppressive niche through cytokine secretion and inhibitory T cell interactions. We identified three temporally distinct cancerassociated fibroblast (CAF) populations displaying unique signatures, and verified these in human datasets. In early tumours, immune CXCL12/CSF1 and complement -expressing CAFs supported recruitment of macrophages, whereas contractile CAFs became more prevalent in later tumours. This study highlights the complex interplay and increasing diversity among cells that co-evolve with the tumour, indicating that from early stages of development, stromal cells acquire the capacity to modulate the immune landscape towards suppression.
Introduction
To aid their growth and development, malignant cells cultivate a supporting niche of 'normal' cells, known as the tumour stroma. This niche comprises non-immune cells such as fibroblasts, blood and lymphatic endothelial cells, as well as numerous immune populations 1 .
In particular, the balance of anti-vs. pro-tumour leukocytes can dictate tumour fate 2,3 , andin many cases suppressive populations persist to support immune escape and prevent tumour clearance. While, immunotherapies such as anti-CTLA4, anti-PD1 and anti-PD-L1 show efficacy in a large number of melanoma patients, a significant proportion do not respond to this treatment [4] [5] [6] [7] . Thus, there remains a critical need to uncover novel therapeutic targets.
The numerous mechanisms through which stromal cells promote tumour growth, represent a wealth of opportunities for therapeutic intervention. However, the evolving tumour microenvironment is extremely dynamic, continually adapting to both soluble and mechanical cues which induce significant heterogeneity within the stromal compartment 8 .
We first sought to delineate relationships within the specific innate immune populations isolated from tumour-associated tissues. Clusters corresponding to macrophages/monocytes, natural killer cells (NK), plasmacytoid DCs (pDC) and conventional DCs (cDCs), were identified based on known markers (Macrophages/Monocytes, Adgre1(F4-80); FcyR1, NK Ncr1; pDCs, Bst2, Siglech; cDCs, Itgax (Cd11c); Fig. 2a , b, c and Supplementary Table 1 ). Moreover, multiple DC populations were observed that reflect the Cd11c+ cDC1 and Cd11c+Cd11b+ (Itgam) cDC2 phenotypes.
cDC1 and cDC2 titles were assigned based on expression of known markers including Clec9a, Baft3 (cDC1), Cd11b and Sirpa (cDC2) ( Fig. 2 c,b) . Two further clusters that lacked lineage markers for adaptive immune cells, as well as ILCs, yet express low Cd11b and Cd11c, were termed migratory DCs due to expression of the DC transcription factor Baft3 and upregulation of Ccr7.
Each DC population further separated according to their location in either the tumour or draining lymph node (Fig. 2a ). Consistent with the steady state, tumour cDC1 cells expressed the dermal DC marker Cd103 (Itgae), whereas the LN population express Cd8a, a marker of lymph node resident cDC1 populations. Cd11b+ MPs in the LN consisted of Adgre1+, Ccr2+ macrophages, as well as a Cd11c+ resident cDC2 population (Fig. 2b) .
Investigation into transcriptional phenotypes of myeloid cells revealed that cells located in the tumour, compared to the lymph node were more activated, yet also displayed immunosuppressive properties. Within tumour MPs, no clear delineation between an M1 or the pro-tumour M2 phenotype was observed, yet chemokines involved in T cell recruitment and suppressive mediators such as Cd274 (PDL1), Arg1, Ido1, Adora2a/b were expressed.
Furthermore, while tumour DC populations displayed increased expression and a wider variety of co-stimulatory molecules, than their lymph node counterparts, they lack expression of cytokines required to induce durable T cell responses. This is particularly relevant in regard to cDC1 cells, which can cross-present tumour antigen to cytotoxic T lymphocytes.
Indeed, while both tumour and LN cDC1 cells upregulate genes involved in crosspresentation pathway, including components of the proteasome (Tap1, Tap and Sec61), expression of these genes was higher in the tumour subset (Extended Data Fig. 3d ).
Although this may indicate that tumour cDC1 populations have increased potential to activate anti-tumour lymphocytes, tumour DCs also expressed immunosuppressive molecules such as Cd274 (PDL1), Pdcd1lg2 (PDL2) and Lgals9 (galectin-9), known to induce T cell exhaustion ( Fig. 2d ). Interestingly, across all myeloid populations, expression of immunosuppressive molecules increased at later time points, whereas co-stimulatory molecules were expressed consistently throughout tumour development. This indicates that tumour resident myeloid populations are present and activated at early stages of tumour growth, yet become more suppressive as the tumour progresses.
T cell populations from tumours and draining lymph nodes were transcriptionally distinct, clustering based upon their subtype, but also location ( Fig. 3a) . At the lymph node, T cells exhibited a more naive phenotype compared to those present at the primary tumour ( Fig.   3b ). While tumour resident CD4+ T cells were more activated, a significant proportion highly expressed Treg-associated genes at the tumour (Fig. 3b) . Similarly, within the CD8+ T cell compartment, those at the tumour were also more activated, expressing high levels of Ifng (IFNγ), Prf1 (perforin) and Gzmb (granzyme B). However, these cells were also less functional, as evident by expression of Pdcd1 (PD1), Lag3 and Tim3 (Fig. 3b ). To identify transcriptional adaptations in CD8+ T cells, at different stages of tumour development, we performed pseudotime analysis that revealed a trajectory of gene expression associated with functional changes in these cells. This confirmed that the majority of T cells within the lymph node were naive displaying high expression of Sell and Tcf7 ( Fig. 3c and d ). Arrival at the tumour corresponded with acquisition of activation signatures, including upregulation of Ifng (IFNγ) and Gzmb (Granzyme B). Furthermore, T cell receptor sequence analysis identified clonal expansion ( Fig. 3c and d ) specifically within tumours at later time points. This was accompanied by expression of the proliferation marker Mki67 and exhaustion markers Pdcd1, Lag3 and Tim3 ( Fig. 3c and d ). Interestingly, a subset of the potentially exhausted CD8 + T cells also showed expression of Entpd1 (CD39), which was recently identified as a marker to distinguish tumour-specific and bystander CD8 + T cells 20 . Together, these results indicate that T cell recruitment from the LN is followed by activation and subsequent functional defects in situ. These functional defects correspond with the gain of immunosuppressive properties in myeloid populations at later time points, indicating that the immune stroma transitions from immunogenic to suppressive phenotypes.
Non-immune stroma comprise three distinct functional populations
As the non-immune stromal components are emerging as immune modulators, we also examined this compartment during tumour progression, focussing on the CAFs. Across all time points, we identified three distinct CAF populations referred to as CAF 1, 2 and 3 ( Fig.   4a ). As expected, expression of commonly used CAF markers was extremely variable across the fibroblasts ( Fig. 4e and Extended Data Fig. 6a ), yet, expression of specific marker combinations correlated with individual clusters. CAF1 could be distinguished from CAF3 by its high levels of Pdpn, Pdgfrα and Cd34, while Acta2 (αSMA) was strongly expressed by the latter population. However, CAF2 represents an intermediate population that was Pdpn + Pdgfrα + and displayed low expression of Acta2 and Cd34 (Fig. 4e ).
Importantly, each cluster displayed distinct functional signatures ( Fig. 4f While these were observed surrounding vessels in adjacent skin, they were rarely associated with intratumoural vessels, but could be detected in peritumoural spindle-shaped cells distinct from the vasculature (Extended Data Fig. 7 c-e).
Our approach highlighted the dynamic nature of CAF populations within a developing tumour. Although each CAF population was detected throughout the time course, different clusters dominated at specific time points. Early day 5 tumours were primarily comprised of fibroblasts from the Pdpn + Pdgfra + CAF1 and 2, whereas the Acta2 high CAF3 population was largely restricted to later stages, implying a selective enrichment in developed tumours. This enrichment may be supported, in part, by our observation of proliferation specifically within CAF2 and 3 ( Fig. 4b ). Proliferation of a subset of CAFs, within the tumour microenvironment, was confirmed by incorporation of the thymidine analogue, EdU (Extended Data Fig. 6c ).
Moreover, the majority of both mouse skin and human skin fibroblasts resembled the cells from CAF1 (Fig. 4e ). Together, this data illustrates that the CAF compartment and its associated functions are dynamic, adapting to localised cues and the changing needs of an evolving tumour.
To validate the existence of these different populations in the tumour microenvironment, we first confirmed each subset based on their unique marker repertoire. Consistent with sequencing data, confocal imaging revealed that CAF markers PDPN and PDGFRα largely colocalised, while expression of αSMA was more distinct (Fig. 5a ). The 'immune' CAF1 marker CD34, colocalized with both PDPN and PDGFRα, indicating the presence of a CD34 high subpopulation. Furthermore, a distinct CD34 high αSMA low CAF subset could be clearly distinguished ( Fig. 5a ). Although at the RNA level, PDPN + PDGFRα + CD34 high CAFs are αSMA -(Extended Data Fig. 6a ), we observed some colocalization between these four markers at the protein level. This may represent the intermediate PDPN + PDGFRα + CAF2 population, which also expressed low levels of CD34 and αSMA.
To examine the inflammatory phenotype associated with the CAF1 population in more detail, we focused on two highly expressed immune modulatory factors, CXCL12 and CSF1.
Using flow cytometry we identified each population using their differential expression of CD34 and αSMA. Tumour fibroblasts were identified using multiple CAF markers, after exclusion of other stromal populations (Extended Data Fig. 8a ), and divided into CD34 high αSMA low (CAF1), CD34 low αSMA low (CAF2) and CD34 low αSMA high (CAF3) subsets. Reflecting our sequencing data, this confirmed CXCL12 expression was highest in the CAF1 subset, followed by intermediate expression in CAF2 and low expression in CAF3 ( Fig. 5b ), this was further verified with RNAscope showing localization of CXCL12 and CD34 + at the RNA level in situ (Extended Data Fig. 6d ). Confocal imaging also confirmed CD34 + CAFs as a source of CSF1 in the tumour stroma both at the protein ( Fig. 5c ) and RNA levels (Extended Data Fig. 6d ). Having validated the presence of these functionally distinct populations, we next evaluated their prevalence at different stages of tumour development (Fig. 5e ). This showed that, as a percentage of the total CAF population, the proportion of of CD34 low αSMA high CAF3 subset was greater at day 11 compared to day 5. This data supports our earlier proposal of a dynamic fibroblast niche, which evolves alongside its malignant tumour core.
Together, these data have identified the presence of distinct CAF populations that dynamically co-evolve with the tumour to support its changing requirements ( Fig. 5g ) and
indicate that CAFs acquire the capacity to influence the tumour immune landscape from early stages of development.
Cross-talk between 'immune'CAFs in infiltrating myeloid cells
Next, we sought to elucidate the potential functional consequences of specific stromal populations to the ensuing immune response. Thus we focused on the early CAF1 "immune" population and examined the cross-talk with responsive immune populations recruited to the tumour. To systematically study interactions within the tumour microenvironment, we in the tumour ( Fig. 6a , Supplementary Table 4 ).
We identified CAF-immune interactions, for example between C3/CXCL12/CSF1-expressing CAFs enriched in early stages of tumour development, and macrophages positive for CXCR4, CSFR1, C3AR1 respectively ( Fig. 6 a, b ). IF imaging of tumour sections allowed us to correlate single cell data with location in situ. Indeed, at the protein level, both CSFR1 + and CXCR4 + macrophages were detected in close contact with CD34 high fibroblasts in the tumour stroma (Fig. 6c ). The combination of transcriptome profiling and cell-cell communication pipeline enabled us to assign these immune interactions specifically to the CAF1/2 subpopulations. Further chemokine-receptor interacting pairs, identified as statistically significant, occured between the immune CAF1 subpopulation, myeloid, Treg and CD8 + T cells (Fig. 6a ). The recruited macrophages exhibited the capacity to both attract T cells, via specific cytokine-receptor signals such as CXCL10, and suppress their function through the PDL1-PD1 axis ( Fig. 6a and d ). Our approach highlighted additional cell-cell communications enriched between tumour infiltrating immune such as recruitment of NK cells through cDC1-cell derived chemokines receptors XCR1 22 . Additionally, we found that the Tregs express high levels of Nt5e (CD73) and Entpd1 (CD39, Fig. 6a and Fig. 3b ), which act together to convert ATP to adenosine who release has been shown to dampen the immune system 23 . The adenosine receptors Adora2a and Adora2b were found upregulated on the migratory DCs and the macrophages respectively.
Collectively, these findings provide new insights into the complex interplay among cells within the evolving tumour microenvironment ( Fig. 6d ), where multiple immunosuppressive mechanisms coexist within an increasingly heterogeneous stromal compartment.
Discussion
It is becoming increasingly evident that non-malignant stromal cells such as endothelial cells, fibroblasts, and infiltrating immune cells found within a tumour, provide significant and varied supporting roles as disease progresses. The heterogeneity and dynamic nature of the tumour microenvironment can make identification of the roles of the different stromal components challenging. The emergence of scRNA-seq has enabled new insights into tumour biology not detectable by previous methods, and has been key to reveal the true degree intratumoural heterogeneity 24, 25 .
In this study, we used a single-cell transcriptomic approach to characterise the stromal landscape within the evolving microenvironment. Our scRNA-seq analysis revealed the gradual development of a suppressive immune microenvironment and defined fibroblast subsets with distinct functional signatures. This approach also highlighted the complexity of cross-talk between the different stromal components as a tumour evolves.
Both clinical studies and the success of immune checkpoint inhibitors have emphasised the importance of the immune system, particularly T cells and macrophages, in deciding tumour fate or response to therapy. While clinical studies have repeatedly demonstrated the presence of exhausted T cells with poor prognosis 2,3 , the steps leading to this point and sites of activation are less clear. Here we showed distinct gene profiles between sites, with lymph nodes acting as a source of naive T cells. Once at the tumour, pseudotime analysis illustrated the trajectory of T cell development within the evolving tumour microenvironment from naive, through clonal expansion and activation (enriched granzyme and IFN expression) phases, to upregulation of exhaustion markers in late tumours (PD1 and Lag3).
A diverse repertoires of myeloid cells were observed within the tumour, and similar to T cells, tumour myeloid populations were more activated than in the lymph node displaying high levels of phagocytosis, antigen presenting and co-stimulatory associated genes. Once at the tumour however, an increase in the level of suppressive factors produced, likely in response to local cues, was detected. Many of these cues served to act upon infiltrating T cell populations to confound the suppressive environment already developing. Moreover, our dynamics data indicates that inhibitory signalling commenced in later phases of tumour development, coinciding with the emergence of T cell dysfunction.
While infiltrating immune populations can have a profound effect on tumour fate, a growing body of evidence indicates that CAFs play a supporting role in the tumour microenvironment 26 Biophysical cues also likely contribute to adaptation of CAF populations. It has been reported that matrix rigidity is critical for the maintenance of CAF phenotypes 34 , and that mechanical and soluble cues are required for the induction of αSMA expression 35 39, 40 . This was reflected in our data, in which expression of multiple pericyte markers was observed in the CAF3 population as well as in PDPN+ lymph node FRCs. A similar phenomenon was reported in a subcutaneous model of breast cancer, in which expression of pericyte markers was also observed in FRC populations 41 . Thus, the most robust method to differentiate between these cell types is to assess whether they are associated with endothelial vessels. In our melanoma model, we observed aSMA, NG2 and MCAM positive cells both associated with vessels and in more peripheral locations. However, the number of vessel associated pericytes was very small, as the majority of vessels were composed of endothelial cells alone. Consequently, CAF3 may embody a mixed population of mesenchymal cells, containing both pericytes and fibroblasts, that share similar surface marker expression and functional properties. Interestingly, the close relationship between these two cell types has led to the suggestion that pericytes may differentiate into activated myofibroblasts during pathology. In both liver and kidney fibrosis, as well as in tumour models, upon the initiation of fibrosis or during growth of malignant cells, pericytes dissociate from the endothelium and begin to express the markers such as αSMA and produce collagen [42] [43] [44] [45] . Therefore, it is possible that fibroblasts within CAF3 may arise from pericyte origins. Overall, this data highlights the limitations of using single marker approaches to isolate and characterise mesenchymal cells, which can lead to contamination and selection bias.
Importantly, and relevant to the clinic, our murine data was mirrored in the setting of human melanoma, with shared patterns of CAF marker expression 24 . Here, CAFs expressing PDPN, PDGFRα and CD34 also clustered together, whereas those expressing αSMA were more distinct. Furthermore, these PDPN + PDGFRα + CD34 + CAFs displayed high expression of CXCL12. Other immunomodulators such as PD-1 ligands and, in particular, complement components were observed in both systems suggesting that the immune function of these populations are a conserved feature and retained in human melanoma. Although the CAF 1/2 clusters were not as distinct as the mouse model, the cohort of CAFs was much smaller.
This discrepancy can be explained by the fact that many of these patients had received immunotherapies prior to resection 24 , and in light of the immunomodulatory capacity of these clusters, we cannot rule out an effect of treatment on the wider stromal landscape.
Our findings also compliment recent investigations into CAF heterogeneity in a range of different solid cancers, each reporting a distinct αSMA + fibroblast phenotype 25, 46, 47 .
Moreover, αSMAfibroblasts highly expressing ECM components, similar to our 'desmoplastic' population have been described in both colorectal and head and neck cancers 25, 46 . Furthermore, in a preclinical model of pancreatic ductal adenocarcinoma (PDAC), another αSMA -CAF population was shown to display an inflammatory profile 47 .
Similarly, a subpopulation of CXCL12-secreting fibroblasts was reported in human breast cancer. However, in contrast to our results, a proportion of this CAF population was αSMA+ 48 . This suggests that the three populations we have identified may be a In summary, we have demonstrated the power of scRNAseq to define the tumour stromal landscape, highlighting the dynamic and adaptive nature of both immune and non-immune stroma within an evolving tumour microenvironment, and revealedpotential cross-talk between these two compartments. We identified 3 CAF clusters with distinct functional and temporal features; the immune subset supporting recruitment and induction of an immunosuppressive macrophage phenotype providing an alternative, indirect mechanism to dampen T cell mediated anti-tumour immunity. 
Materials and Methods

Mouse models
Isolation of Single Cells
Single cells were isolated from processed tissues using fluorescence-activated cell sorting 
Preparation of cDNA and sequencing
Reverse transcription and cDNA pre-amplification were performed according to the SmartSeq2 protocol 60 
Single-cell RNA sequencing analysis
The SmartSeq2 data was quantified with Salmon 61 (version 0.8.2), using the GENCODE mouse protein-coding transcript sequences. Transcript Per Million (TPM) values reported by Salmon were used for the quality control of the samples. In order to get the endogenous TPM values, we removed the ERCC's from the expression table and scaled the TPM's so that they sum to a million. Cells with less than 1500 detected genes and for which the total mitochondrial expression exceeded 20% were excluded from further analysis. Genes that were expressed in less than 3 cells were also removed.
Downstream analysis such as, clustering based on SNN graph-based clustering, differential expression analysis and visualisation were performed using the Seurat package 19 We also removed a cluster for which the top markers were genes associated with dissociation-induced effects.
To further identify subpopulations, we reanalysed the T cells, innate immune cells (myeloid and NK) and the CAFs separately, using the same workflow as described above. To account for the cell cycle heterogeneity in the T cell subsets. a cell cycle score was calculated for each cell and this score was then regressed out. We used the function "AddModuleScore"
from Seurat and the list of G2M associated genes from Scaldoen et al. to calculate a cell cycle score for each cell.
Gene Set Enrichment Analysis (GSEA) (software.broadinstitute.org/gsea/index.jsp) was performed on genes that were differentially expressed between clusters, with a p value < 0.05. Overlap with canonical GO categories (CP:BIOCARTA, CP:KEGG, CP:REACTOME) was assessed and the False Discovery Rate (FDR) calculated.
T-cell receptor (TCR) analysis
The TCR sequences for each single T cell were assembled using TraCeR 63 which allowed the reconstruction of the TCRs from scRNA-seq data and their expression abundance (transcripts per million, TPM), as well as identification of the size, diversity and lineage relation of clonal subpopulations. In total, we detected 77 TCR sequences with at least one paired productive αβ or gamma-delta chain. Cells for which more than two recombinants were identified were excluded from further analysis.
Cell cycle analysis
The pair-based prediction method described by Scialdone et al 64 . and implemented in the R package scran was used to assign each cell a cell cycle stage. Briefly, using a training data, pairs of marker genes are identified such that the expression of the first gene in the training data is greater than the second in certain cell cycle stage but less than the second in all other stages. For each cell then, the method calculates the proportion of all marker pairs where the expression of the first gene is greater than the second in the test data.
Putative interactions between cell types
To enable a systematic analysis of cell-cell communication, we used CellPhoneDB (Vento-Tormo, Efremova et al., Nature, in press). CellPhoneDB is a manual curated repository of ligands, receptors and their interactions, integrated with a new statistical framework for inferring cell-cell communication networks from single cell transcriptome data. Briefly, in order to identify the most relevant interactions between cell types, we looked for the cell-type specific interactions between ligands and receptors. Only receptors and ligands expressed in more than 10% of the cells in the specific cluster were considered. We performed pairwise comparisons between all cell types. First, we randomly permuted the cluster labels of all cells 1000 times and determined the mean of the average receptor expression level of a cluster and the average ligand expression level of the interacting cluster. For each receptorligand pair in each pairwise comparison between two cell types, this generated a null distribution. By calculating the proportion of the means which are "as or more extreme" than the actual mean, we obtained a p-value for the likelihood of cell type-specificity of a given receptor-ligand complex. We then prioritized interactions that are highly enriched between cell types based on the number of significant pairs and manually selected biologically relevant ones. For the multi-subunit heteromeric complexes, we required that all subunits of the complex are expressed (using a threshold of 10%), and therefore we used the member of the complex with the minimum average expression to perform the random shuffling.
Mouse skin fibroblasts from healthy mice
Skin samples from two 8-week old female C57BL/6 mice were processed, first by mechanical processing, followed by 2 h incubation with 0.5% collagenase B (Roche; 11088815001). Cells were then counted and loaded on the 10x Chromium machine.
Libraries were prepared following the Chromium Single Cell 3′ v2 Reagent Kit Manual 65 .
Libraries were sequenced on an Illumina HiSeq 4000 instrument with 26 bp for read 1 and 98 bp for read 2.
Droplet-based sequencing data was aligned, filtered and quantified using the Cell Ranger
Single-Cell Software Suite (version 2.2.0), against the mouse reference genome provided by Cell Ranger. The data was analysed using the pipeline described above. Only the clusters identified as fibroblasts (based on expression of Col1a1, Col1a2) were considered for comparison with the CAF clusters.
Human skin fibroblasts
scRNA-seq data was downloaded from ArrayExpress (E-MTAB-6831) 66 . CD45-negative cells from a digested skin sample were taken from a human female and processed in a 10X
Chromium machine (10X Genomics). Droplet-based sequencing data was aligned, filtered and quantified using the Cell Ranger Single-Cell Software Suite (version 1.2.0), against the GRCh38 human reference genome provided by Cell Ranger. The data was analysed using the pipeline described above. Only the clusters identified as fibroblasts (based on expression of COL1A1, COL1A2) were considered for comparison with the CAF clusters.
Comparison of human and mouse skin fibroblasts with CAFs
To compare the mouse and human skin fibroblasts with the CAFs, a logistic regression with L2-norm regularization and a multinomial learning approach (implemented by the scikit-learn function LogisticRegression) was trained on the CAF clusters, using the log-transformed normalized data. The model was used to predict the probabilities of each mouse and human skin cell belonging to each one of the CAF clusters (implemented by the predict_proba function).
Flow Cytometry
Following a 20min incubation with a fixable fluorescent viability stain (see isolation of single cells), cells were incubated with primary antibodies, against cell surface markers, for 30mins at 4 o C. All primary antibodies were diluted according to 
EdU Incorporation
B16 melanomas were established in wt C57BL/6 mice as previously stated. Tumours were collected after 11 days and frozen in OCT medium for histology. Intraperitoneal injections of 500μg/ml of 5-ethynyl-2'-deoxyuridine (EdU) were performed every 24hs, 4 days prior to culling. Sections were fixed at -20 o C, in a mixture of acetone and methanol (50:50) . After fixation, the EdU Click-it Alexa Fluor 647 kit (Invitrogen) was used to visualise incorporated EdU, according to the manufacturer's protocol. Following the click-it reaction, antibody staining was performed as previously stated. 
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